CoreCivic offers politically leveraged value: powerful cash-flow upside from immigration-driven facility demand, offset by severe regulatory and customer-concentration risk.
CoreCivic Inc (CXW) operates as a diversified real estate investment trust and the largest private owner of partnership correctional, detention, and residential reentry facilities in the United States.[1, 2] The company's business model is structured around three primary segments: CoreCivic Safety, CoreCivic Community, and CoreCivic Properties.[3] CoreCivic Safety constitutes the operational backbone of the firm, managing 44 secure correctional and detention facilities with an aggregate design capacity of 67,785 beds, which generated 91.7% of total segment net operating income in the fiscal year ending late 2025.[3] CoreCivic Community provides alternative-to-incarceration and transitional services, operating 20 residential reentry centers with a design capacity of 4,099 beds (5.1% of segment net operating income).[3] CoreCivic Properties leases five correctional properties directly to third-party government entities under long-term real estate lease agreements, contributing 3.2% of segment net operating income.[3]
The company generates its revenues through per-diem operational contracts and flat-rate monthly leases with government agencies.[2] Its primary customer types are concentrated in federal, state, and local government entities.[4, 5] During the first quarter of 2026, federal partners comprised 58% of CoreCivic's total revenue, highlighted by U.S. Immigration and Customs Enforcement (ICE)—the company's largest customer—which contributed $261.3 million or 42.5% of total revenue during the quarter.[4, 5] The U.S. Marshals Service acts as the second-largest customer [6], while state departments of corrections (including Georgia, Montana, and Colorado) and municipal governments make up the remainder of the portfolio.[4] Geographically, CoreCivic's assets are concentrated in the South and Southwest regions of the United States, positioning it close to areas with high state-level and border-related bed demand.[2]
CoreCivic's core products and services encompass comprehensive secure custody, specialized medical and mental healthcare (recently bolstered by its $148 million pharmacy acquisition), vocational training, substance abuse rehabilitation, and secure inter-facility transportation.[5, 7, 8] Government customers choose CoreCivic over public alternatives primarily due to severe budgetary constraints, extreme facility overcrowding, and the significant cost efficiencies provided by private operators.[8] Private prison contracts typically reduce per-diem inmate costs by 10% to 15% compared to publicly operated facilities.[8] Furthermore, CoreCivic offers turnkey operational flexibility, allowing government partners to rapidly activate idle beds during population surges, backed by minimum occupancy guarantees of 80% to 100% that guarantee baseline revenue even when beds are unoccupied.[9]
CoreCivic sells a highly integrated operational service suite. Its main revenue generator is "compensated man-days," which refers to the daily per-diem rate paid by government entities to house and secure detainees.[2, 3] The company provides 24/7 security, facility management, and professional dietary services.[8, 10] Following its recent $148 million vertical acquisition of Clinical Solutions Pharmacy in early 2026, CoreCivic now packages institutional pharmacy services directly with its correctional healthcare, reducing operational friction and capturing a high-margin, adjacent revenue stream.[5, 7] Reentry programs include academic coursework, vocational training (designed to reduce recidivism), and cognitive behavioral therapy.[8] In the Community segment, CoreCivic sells transitional housing and partners with electronic monitoring providers to support community-based supervision.[2, 3]
CoreCivic is insulated by a powerful, asset-heavy competitive moat that makes market replication nearly impossible:
The global private prison service market was valued at $10.8 billion in 2025 and is projected to reach $17.6 billion by 2034, representing a stable CAGR of 5.6%.[8] North America dominates the TAM, commanding a 47.2% revenue share, equivalent to approximately $5.1 billion in 2025.[8] The addressable market is structurally supported by aging public infrastructure and overcrowding.[8, 13] This driver is further amplified by a dramatic rise in federal immigration enforcement and border-related policing budgets, which grew from $20 billion in 2017 to $54.3 billion in 2025, expanding at a 2.7x multiple and representing the fastest-growing legal system expense in the United States.[14] This budget expansion translates directly into heightened demand for private bed space.[15]
CoreCivic operates in a duopoly with The GEO Group, which manages a comparable number of beds but carries a higher debt load and has a larger presence in alternative-to-incarceration technology (such as ankle monitors) and secure transportation.[2, 16, 17] While GEO Group holds a larger direct share of ICE detention capacity (roughly 24,000 detainees), CoreCivic maintains a superior capital structure with lower leverage metrics, enhancing its financial flexibility.[2, 16, 17] CoreCivic is holding its ground, actively reactivating idle facilities to capture market share.[5, 18] Since early 2025, CoreCivic has reactivated five previously idled facilities—including West Tennessee, California City, Diamondback, and Leavenworth’s Midwest Regional Reception Center—adding over 7,700 active beds to meet federal demand.[4, 18]
CoreCivic reported its first-quarter 2026 financial results on Wednesday, May 6, 2026, delivering performance that beat analyst consensus expectations across all key metrics.[4, 19]
| Metric | Q1 2026 Reported | Q1 2025 Reported | Year-over-Year Change | Analyst Consensus | Performance vs. Consensus |
|---|---|---|---|---|---|
| Total Revenue | $614.7 million | $488.6 million | +25.8% | $604.37 million | Beat by 1.71% [4, 5] |
| Net Income | $37.9 million | $25.1 million | +51.0% | N/A | Beat Internal Forecasts [4] |
| GAAP Diluted EPS | $0.38 | $0.23 | +65.2% | N/A | Beat Internal Forecasts [4, 20] |
| Adjusted Diluted EPS | $0.40 | $0.23 | +73.9% | $0.28 | Beat by 42.86% [4, 5] |
| Normalized FFO / Share | $0.65 | $0.45 | +44.4% | $0.35 | Beat by 85.71% [4, 21] |
| Adjusted EBITDA | $110.1 million | $81.0 million | +36.0% | N/A | Beat Internal Forecasts [4] |
An analytical nuance arises from reported earnings data: the company's Normalized Funds From Operations (FFO) reached $0.65 per diluted share.[4] Some data trackers compared this $0.65 figure directly against the $0.28 EPS consensus estimate, reporting a massive earnings surprise, while Adjusted Diluted EPS actually came in at $0.40, still representing a substantial 42.86% beat.[4, 5, 19]
The primary driver of the strong top- and bottom-line outperformance was the activation of four previously idled facilities since the first quarter of 2025 and the acquisition of the Farmville Detention Center.[4] This resulted in average daily managed populations rising 11.3% to 57,243 individuals, pushing safety and community occupancy to 79.6% (up from 77.0% in Q1 2025).[5, 18] Consequently, management revenue from ICE surged 96.2% year-over-year to $261.3 million.[4] This growth was partially offset by a transition in inmate populations at the Trousdale Turner facility, which elevated startup and guard wage expenses during the quarter.[18]
Reflecting strong operational momentum, CoreCivic updated its full-year 2026 financial guidance during its May earnings call [5, 22]:
| Metric | Updated FY 2026 Guidance | Prior FY 2026 Guidance |
|---|---|---|
| Net Income | $147.8 million to $157.8 million | $147.5 million to $157.5 million [22] |
| Diluted EPS | $1.51 to $1.61 | $1.49 to $1.59 [22] |
| Adjusted Diluted EPS | $1.53 to $1.63 | $1.49 to $1.59 [22] |
| FFO per Diluted Share | $2.58 to $2.68 | $2.54 to $2.64 [22] |
| Normalized FFO / Share | $2.60 to $2.70 | $2.54 to $2.64 [22] |
| Adjusted EBITDA | $453.8 million to $461.8 million | $437.0 million to $445.0 million [22] |
The guidance increase was driven by the strong Q1 outperformance (adding $0.05 per share), the Leavenworth facility activation (contributing $0.05 to $0.06 per share), and accretion from the Clinical Solutions Pharmacy acquisition (contributing $0.03 to $0.05 per share).[5] These catalysts were partially offset by a $0.09 to $0.15 per share reduction due to a temporary decline in nationwide ICE populations.[5]
Investors should monitor several near-term headwinds highlighted by management.[5] First, nationwide ICE populations in CoreCivic facilities declined by approximately 3,000 individuals between late January and April 2026, dropping from a peak of nearly 70,000 to slightly under 60,000.[5] This temporary decline was driven by a government shutdown that forced the temporary redeployment of ICE agents to assist TSA security personnel, slowing detainee intake.[5, 18] Management noted that this is transitionary and expects populations to return to the 70,000 range in the second half of 2026.[5, 18]
Second, management provided specific modeling guidance for the second quarter of 2026 [5]:
* Q2 2026 EPS will reflect a $0.06 reduction due to the seasonal recognition of CARES Act employee retention credits in Q1.[4, 5]
* Lower average ICE populations are expected to create a $0.05 to $0.07 per share headwind compared to Q1.[5]
* These headwinds will be partially offset by a $0.01 to $0.02 seasonal benefit, as Q1 is historically weaker due to front-loaded annual unemployment taxes.[5]
As of March 31, 2026, CoreCivic held a cash balance of $209.7 million.[7] However, total debt expanded to $1.41 billion (up from $1.23 billion at year-end 2025), driven by $425 million drawn on its expanded $575 million revolving credit facility.[7] To fund working capital requirements as facilities ramp up, CoreCivic amended its bank facility on April 10, 2026, to secure a $100 million incremental 364-day term loan.[5, 15] Net leverage (net debt-to-Adjusted EBITDA) stood at 2.8x trailing twelve months.[4]
The market reacted highly favorably to the Q1 2026 results.[10] CoreCivic's stock price surged 12.36% in after-hours trading immediately following the May 6 announcement, closing at $21.82 on May 7, 2026.[10, 23] The stock continued to gain ground, closing at $26.45 by June 10, 2026.[23] Analysts responded by maintaining positive ratings and raising price targets, with Benchmark targeting $28.00 and Jones Trading targeting $30.00.[19]
CoreCivic's valuation is driven by its high operating leverage.[13, 24] The company's real estate footprint carries significant fixed costs (staffing, physical security, utilities).[3] Once a facility's fixed costs are cleared, incremental detainee occupancy flows to the bottom line at high margins.[4]
Currently, CoreCivic trades at a trailing price-to-sales multiple of 1.07x and an enterprise-value-to-EBITDA multiple of 9.84x, reflecting a discount to its historical sector average of 12x to 14x FFO.[25, 26] This discount is driven by political and regulatory headlines rather than operational fundamentals.[25] Historically, CoreCivic's 5-year sales growth CAGR has been stable at approximately 3.40%.[20] However, the current contract activation cycle has accelerated top-line growth to 12.69% in 2025 and 25.8% in Q1 2026, which is driving a major fundamental re-rating.[4, 27]
The investment thesis for CoreCivic is exposed to several critical risk vectors, ranging from company-specific execution issues to macroeconomic and geopolitical developments.
┌─────────────────────────┐
│ VULNERABILITY LEVEL │
└────────────┬────────────┘
│
┌────────────────────────┼────────────────────────┐
▼ ▼ ▼
┌──────────────────┐ ┌──────────────────┐ ┌──────────────────┐
│What Could Go Wrong│ │Early Warning Sign│ │Long-Term Damage │
├──────────────────┤ ├──────────────────┤ ├──────────────────┤
│• Executive order │ │• National ICE │ │• A permanent │
│ banning private │ │ populations drop│ │ federal ban on │
│ contract detent-│ │ below 50,000 for│ │ all physical │
│ ion facilities │ │ over two consec-│ │ contract deten- │
│ nationwide. │ │ utive quarters. │ │ tion assets. │
└──────────────────┘ └──────────────────┘ └──────────────────┘
This scenario analysis projects CoreCivic’s total return trajectory over a 5-year horizon (ending in 2031), utilizing the current share price of $26.45 as the baseline.[23]
The Base Case assumes that the current federal enforcement funding remains stable, and CoreCivic successfully ramps up and stabilizes its five newly activated facilities.[18]
The High Case assumes an aggressive escalation in immigration detention demand, alongside successful execution of adjacent businesses such as the Clinical Solutions Pharmacy.[5]
The Low Case reflects a hostile federal political shift, including executive orders or legislation restricting private federal detention contracts.[15]
| Scenario | Current Price | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 (Exit) |
|---|---|---|---|---|---|---|
| High Case | $26.45 | $30.00 | $34.00 | $38.50 | $43.20 | $48.30 USD |
| Base Case | $26.45 | $26.90 | $27.30 | $27.80 | $28.20 | $28.62 USD |
| Low Case | $26.45 | $21.00 | $16.50 | $12.00 | $9.20 | $7.30 USD |
Applying the subjective probability weights to the projected Year 5 share prices yields a probability-weighted price target:
$\text{Weighted Price Target} = (0.30 \times \$48.30) + (0.50 \times \$28.62) + (0.20 \times \$7.30) = \$14.49 + \$14.31 + \$1.46 = \$30.26 \text{ USD}$
| Scenario | Revenue in Year 5 | Margin / Earnings Assumption | Valuation Multiple Assumption | Current Share Price | Implied Future Share Price | 5-Year Total Return | Annualized Return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | $3.35 Billion | 7.50% Net Margin / $251.3M Net Income | 15.0x P/E | $26.45 [23] | $48.30 USD | +82.61% | +12.80% | 30% |
| Base Case | $2.90 Billion | 6.20% Net Margin / $179.8M Net Income | 13.5x P/E | $26.45 [23] | $28.62 USD | +8.20% | +1.59% | 50% |
| Low Case | $2.05 Billion | 3.50% Net Margin / $71.8M Net Income | 10.0x P/E | $26.45 [23] | $7.30 USD | -72.40% | -22.70% | 20% |
ASYMMETRIC GROWTH OVERHANG
The leadership transition in January 2026 was highly organized, with long-term President and COO Patrick Swindle seamlessly succeeding Damon Hininger as CEO.[31] Swindle brings 18+ years of internal operational experience.[32] Board stock ownership guidelines are strictly enforced to align executive interests with shareholders.[33] Blackrock and River Road Asset Management maintain large stakes (16.4% and 9.1% respectively), providing robust institutional oversight.[33] However, Swindle’s direct ownership is low at 0.2% of outstanding shares [34], and recent insider sales by other executives (such as CAO Cole Carter) slightly detract from a perfect alignment score.[19]
The presence of minimum occupancy guarantees (80% to 100%) in several contracts creates highly predictable cash flows when active.[9] However, the severe concentration of revenue with ICE and other federal entities (58% of total revenue) exposes the top line to extreme regulatory and political volatility.[5]
CoreCivic commands an estimated 40% market share of the private US correctional market.[2] Alongside GEO Group, it operates as a stable duopoly protected by immense physical plant replacement costs and statutory regional barriers that prevent new competitors from entering.[2, 12]
Near-term growth is exceptionally robust as CoreCivic completes the ramp-up of its recently activated facilities, adding more than 7,700 beds of high-margin capacity.[18] However, long-term growth is fundamentally constrained by regional physical capacity and political risks that prevent secular expansion.[15]
The company generates highly reliable operating cash flow.[29] However, leverage of 2.8x Adjusted EBITDA is at the high end of its target range, and total debt is elevated at $1.41 billion.[4, 7] The addition of a $100 million short-term working capital loan highlights near-term liquidity tightening ahead of the major 2027 debt maturity wall.[5, 15]
Correctional and secure immigration detention infrastructure remains chronically under-supplied in the United States, providing a highly durable demand baseline.[13] However, the systemic threat of a legislative ban on private contracts at the federal level represents a permanent viability overhang.
Management continues to execute a highly shareholder-friendly capital strategy.[4] In 2025, the company repurchased 11.2 million shares for $218.4 million [3], followed by another 2.3 million shares in Q1 2026.[4] While dividend payments remain suspended, this capital preservation is highly prudent given current refinancing needs.[26, 29]
Consensus Wall Street opinion is highly positive, with multiple active buy ratings and price targets ranging from $28.00 to $30.00.[19, 35] Strong consecutive quarterly earnings beats have significantly boosted near-term analyst revisions.[21]
With a trailing net margin of 5.5% and a return on equity of 9.3%, CoreCivic demonstrates steady corporate profitability.[30] Margins are temporarily compressed by pre-activation and startup expenses at newly reopened facilities, but they possess significant operating leverage.[2, 22]
CoreCivic has grown earnings at a 35.7% average annual rate over the past five years.[20] However, the historic suspension of its REIT status and dividend in 2020, alongside cyclical price collapses during negative political regimes, has impaired long-term historical shareholder value creation.
RESILIENT BUT VOLATILE
CoreCivic is currently navigating a period of rapid, highly profitable operational expansion.[18] The activation of five previously idled facilities since early 2025 has dramatically expanded the company's revenue run-rate.[4, 18] These reactivations, alongside the vertical integration of Clinical Solutions Pharmacy, provide near-term earnings catalysts that are yet to be fully captured by current multiples.[5, 15]
The primary investment thesis hinges on a structural supply-demand imbalance.[2, 13] The government lacks the modern facility capacity to manage severe overcrowding and rising border enforcement needs, forcing continued reliance on CoreCivic's high-barrier infrastructure.[8] Under current federal policies, the company is fundamentally undervalued relative to its forward cash-generation run-rate.[15, 25]
However, investors must remain cognizant of the severe political overhang.[15] Any structural regulatory shift away from contracted physical detention represents a permanent ceiling on valuation multiples and a catastrophic tail risk.[15, 25] In conclusion, CoreCivic presents an asymmetric valuation opportunity, where strong cash flow generation and aggressive share repurchases provide immediate support, but long-term multiple expansion remains tightly bound to political cycles.[4, 15]
Note: This report is for analytical purposes only and does not constitute financial advice or investment recommendations.
POLITICALLY LEVERAGED VALUE
CoreCivic's stock price (trading at $26.45 as of June 10, 2026) has exhibited powerful upward momentum, climbing significantly above its 200-day moving average of $19.39 and its 50-day moving average of $20.69.[23, 26] The technical setup is highly positive following a multi-month breakout driven by consecutive earnings beats and the expansion of its revolving credit facility.[21, 24] Despite a temporary technical MACD histogram turn to negative in early June, the stock is trending strongly, though it faces short-term overhead resistance near its newly established 52-week high of $25.40 (surpassed on June 10 to $26.45).[23, 26, 36]
BULLISH MOMENTUM EXTENDED
View CoreCivic, Inc. (CXW) stock page
Loading the interactive version of this report…